For the Inventor, By the Inventor

Enter assignee name

Fremont, CA, United States of America

Ardelyx, Inc.

USPTO Granted Patents = 39

CIPO Patents = 1

EPO Patents = 23

Forward Citations = 68

Loading Chart...

Loading Chart...

34 inventors (with patents filed for the assignee):

Jeffrey William Jacobs (29 out of 43 patents)

Dominique Charmot (25 out of 113 patents)

Jason Gustaf Lewis (25 out of 29 patents)

4. Michael Robert Leadbetter (22 out of 66 patents)

5. Christopher Carreras (20 out of 27 patents)

6. Noah Bell (20 out of 20 patents)

7. Eric Labonte (16 out of 16 patents)

8. Marc Navre (15 out of 15 patents)

9. Tao Chen (14 out of 229 patents)

10. Dean R Dragoli (9 out of 33 patents)

11. Han-Ting Chang (8 out of 32 patents)

12. Nicholas Reich (8 out of 8 patents)

13. Rakesh K Jain (7 out of 34 patents)

14. Jeremy Caldwell (7 out of 7 patents)

15. Ingrid Langsetmo (7 out of 7 patents)

Core Competencies:

Gastrointestinal Tract Disorders

Metabolic Conditions

Phosphate Transport

NHE-Mediated Antiport

Hyperkalemia Treatment

Hormone Receptor Modulators

TGR5 Agonists

FXR Activators

Fluid Retention

Salt Overload

4-Phenyl Pyridine Compounds

Glycyrrhetinic Acid Derivatives

39 patents: Sort by Forward Citations

1. 12281103 - Compounds useful for treating gastrointestinal tract disorders (2025-04-21),

2. 12209088 - Hormone receptor modulators for treating metabolic conditions and disorders (2025-01-28),

3. 12084472 - Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists (2024-09-10),

4. 12016856 - Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders (2024-06-25),

5. 11858959 - Glycyrrhetinic acid derivatives for use in treating hyperkalemia (2024-01-02),

6. 11813304 - Compounds and methods for inhibiting phosphate transport (2023-11-14),

7. 11768319 - Glycyrrhetinic acid derivatives for treating hyperkalemia (2023-09-26),

8. 11753410 - Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders (2023-09-12),

9. 11718619 - Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators (2023-08-08),

10. 11318129 - Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders (2022-05-03),

11. 11242337 - Compounds useful for treating gastrointestinal tract disorders (2022-02-08),

12. 11147884 - Inhibitors of NHE-mediated antiport (2021-10-19),

13. 11091482 - Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators (2021-08-17),

14. 10968246 - Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists (2021-04-06),

15. 10940146 - NHE3-binding compounds and methods for inhibiting phosphate transport (2021-03-09),

Ardelyx, Inc. is a biopharmaceutical company based in Fremont, California, focused on developing innovative therapies for patients with gastrointestinal and renal diseases. The company specializes in the discovery and commercialization of novel compounds that target unmet medical needs, particularly in areas such as chronic kidney disease and irritable bowel syndrome. Ardelyx leverages its expertise in drug development to advance treatments that improve patient outcomes and enhance quality of life.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

39 Patents

#55 in Fremont, CA

#2,088 in California

#8,814 in US

#17,428 in the World

Fremont, CA, United States of America

Ardelyx, Inc.

Forward Citations = 68

34 inventors:

Jeffrey William Jacobs (29 out of 43 patents)

Dominique Charmot (25 out of 113 patents)

Jason Gustaf Lewis (25 out of 29 patents)

4. Michael Robert Leadbetter (22 out of 66 patents)

5. Christopher Carreras (20 out of 27 patents)

Please report any incorrect information to [email protected]

Loading…